07-05-2025
Sigachi Industries receives Certificate of Suitability for Metformin Hydrochloride from EDQM
By Aman Shukla Published on May 7, 2025, 12:48 IST
Sigachi Industries Limited has recently received the Certificate of Suitability (CEP) for Metformin Hydrochloride from the European Directorate for the Quality of Medicines & Health Care (EDQM) on May 5, 2025. This certification underscores Sigachi's adherence to quality standards, regulatory compliance, and its readiness for global markets.
Metformin Hydrochloride, a common medication for managing type 2 diabetes, is projected to reach a market value of USD 386.91 million by 2030, growing at a compound annual growth rate (CAGR) of approximately 4.7%. Several Metformin-based Fixed Dose Combinations (FDCs) have already been approved by the U.S. Food and Drug Administration (USFDA), including products like Glucovance, Actoplus Met, Janumet, and others. These approvals highlight the recognized role of Metformin-based therapies in diabetes care.
The CEP certification for Metformin Hydrochloride is in line with Sigachi's ongoing strategy to strengthen its presence in regulated markets, ensuring the company meets the European Union's stringent safety, efficacy, and Good Manufacturing Practice (GMP) requirements.
Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, commented, 'This achievement aligns perfectly with our vision of expanding into highly regulated markets and strengthen our position in the global pharmaceutical industry. With the rising demand for Metformin-based therapies, Sigachi is committed to leveraging its R&D expertise and state-of-the-art facilities to deliver pharmaceutical solutions that meet international standards and address the dynamic needs of the healthcare sector.'
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
